**What is already known about the topic?**

-   End-stage liver disease is a major cause of morbidity and mortality worldwide, causing symptoms and reducing health-related quality of life.

-   There are no systematic reviews of symptom prevalence or health-related quality of life of patients with end-stage liver disease.

**What this paper adds?**

-   The symptom prevalence of patients with end-stage liver disease resembled that of patients with other advanced conditions.

-   The most frequently reported symptoms were pain, breathlessness, muscle cramps, sleep disturbance, depression, anxiety, and erectile dysfunction.

-   Decompensation led to significant worsening of health-related quality of life.

**Implications for practice, theory, or policy**

-   Given the diversity of symptoms and significantly impaired health-related quality of life, multidisciplinary approach and timely intervention are crucial in the care of patients with end-stage liver disease.

Introduction {#section7-0269216318807051}
============

End-stage liver disease is the final stage of a liver disease when liver failure is usually irreversible and liver transplantation is the only curative treatment. Worldwide, end-stage liver disease is a common cause of morbidity and mortality.^[@bibr1-0269216318807051][@bibr2-0269216318807051][@bibr3-0269216318807051][@bibr4-0269216318807051][@bibr5-0269216318807051]--[@bibr6-0269216318807051]^ A global estimate of its mortality in 2010 reported more than 1 million patients died from end-stage liver disease equating to about 2% of all deaths.^[@bibr4-0269216318807051],[@bibr5-0269216318807051]^ In Europe, liver disease is the seventh leading cause of death.^[@bibr6-0269216318807051]^ In the United Kingdom, liver disease is currently the fifth most common cause of death in those under 65 years of age, and the number of people who die from end-stage liver disease is still increasing.^[@bibr1-0269216318807051]^ In the United States, end-stage liver disease is the 12th leading cause of death overall, and the 7th leading cause of death in people aged 25--64 years.^[@bibr2-0269216318807051]^ Compared to other end-stage organ failure or terminal illness, end-stage liver disease disproportionately affects younger age groups, and the years of life lost is estimated to be around 20 years.^[@bibr7-0269216318807051],[@bibr8-0269216318807051]^

Cirrhosis, which is defined as the histological development of advanced liver fibrosis, is a final pathway in patients with chronic liver injury from a variety of etiologies.^[@bibr9-0269216318807051],[@bibr10-0269216318807051]^ Alcoholic liver disease and hepatitis C are the main causes in developed countries, while hepatitis B is the most common cause in most parts of Asia and sub-Saharan Africa.^[@bibr10-0269216318807051]^ Patients with cirrhosis who have not developed major complications are classified as having compensated cirrhosis. As progressive liver damage occurs, the disease may proceed to decompensated cirrhosis, that is, end-stage liver disease. The major complications of decompensation include variceal bleeding, ascites, encephalopathy, spontaneous bacterial peritonitis, hepatorenal syndrome, and hepatopulmonary syndrome. Once decompensation has occurred, the 5-year mortality without transplantation is as high as 85%.^[@bibr10-0269216318807051]^ Patients with end-stage liver disease face physical, psychological, and complex social and financial problems because the majority of them are in their working age.^[@bibr7-0269216318807051],[@bibr11-0269216318807051]^

Although patients with end-stage liver disease are vulnerable and at risk of death, it is surprising that such little attention has been paid to describing their symptom prevalence and health-related quality of life. Another problem comes from the ambiguous study population representing patients with end-stage liver disease in previous research, such as patients with chronic liver disease, advanced liver disease, or liver cirrhosis without mentioning decompensation or not. Furthermore, studies looking into health-related quality of life of patients with end-stage liver disease have predominantly focused on the health-related quality of life of liver transplant recipients, not of candidates experiencing end-stage liver disease.^[@bibr12-0269216318807051]^

This study aimed to describe symptom prevalence and health-related quality of life of patients with end-stage liver disease in order to understand their needs and to provide a good reference for developing tailored care services for them.

Materials and methods {#section8-0269216318807051}
=====================

Study design {#section9-0269216318807051}
------------

We undertook a systematic review and meta-analysis, which was conducted and reported following the PRISMA (preferred reporting items for systematic reviews and meta-analyses) statement.^[@bibr13-0269216318807051]^

Search strategy and selection criteria {#section10-0269216318807051}
--------------------------------------

We searched eight electronic databases including Cochrane Library (Wiley), MEDLINE (Ovid), EMBASE (Ovid), PsycINFO (Ovid), CINAHL (EBSCO Host), British Nursing Index (ProQuest), SCOPUS (Elsevier), and Web of Science (Thomson Reuters), between 1 January 1980, and 30 June 2018, using a combination of medical subject headings, title/abstract keywords, and free text (see [Supplementary Material](http://journals.sagepub.com/doi/suppl/10.1177/0269216318807051)). In addition to database searching, hand searching (from reference lists of all of the eligible studies, key studies, and key journals) was performed. No language restrictions were applied, and the full eligibility criteria are presented in [Table 1](#table1-0269216318807051){ref-type="table"}.

###### 

Eligibility criteria for the systematic review.

![](10.1177_0269216318807051-table1)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Component          Criteria
  ------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study population   *Inclusion criteria*\
                     • Adults (⩾18 years old)\
                     • End-stage liver disease (ESLD), with evidence of at least one of the following:\
                      (1) Liver cirrhosis, with at least an index clinical complication of decompensation\
                      (2) Liver cirrhosis, being referred for liver transplantation evaluation\
                      (3) Liver cirrhosis, with Child--Turcotte--Pugh (CPT) classification predominantly B or C of the study population (Child A ⩽ 40%, or mean/median CPT score \> 7)\
                      (4) Patients being referred for liver transplantation evaluation, with clear description of the etiology from chronic/advanced liver disease\
                      (5) Liver transplantation candidates, liver cirrhosis related (or with clear description of the etiology from chronic or advanced liver disease)\
                     *Exclusion criteria*\
                     • Under 18 years old\
                     • Acute hepatic failure\
                     • Metabolic liver diseases (e.g. familial amyloid polyneuropathy)\
                     • Having other terminal diseases (except hepatocellular carcinoma)\
                     • Liver transplantation candidates waiting for combined liver and kidney transplantation\
                     • Liver transplant recipients only

  Study design       *Inclusion criteria*\
                     Peer-reviewed clinical controlled trials or observational studies were eligible\
                     *Exclusion criteria*\
                     Review articles, discussions, letters, editorials, comments, case reports, case series, case studies, and qualitative studies were not considered. Before and after studies focusing on the change in quality of life by liver transplantation were excluded

  Outcome            Any outcome related to symptom prevalence or health-related quality of life was eligible

  Language           No language restrictions
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Following the search, two authors (J.-K.P. and N.H.) screened all titles and abstracts and excluded irrelevant papers independently. Then J.-K.P. assessed the full texts of all the remaining studies and discussed with N.H. as needed. Disagreement was resolved via discussion.

Data analysis {#section11-0269216318807051}
-------------

Data were extracted from all included studies (by J.-K.P.) using a data extraction spreadsheet. For each study, author/year, place of study, study design, study population, patient number, age, sex, etiology, Child--Turcotte--Pugh classification (or score),^[@bibr14-0269216318807051]^ percentage of patients with hepatocellular carcinoma, Model for End-Stage Liver Disease score,^[@bibr15-0269216318807051][@bibr16-0269216318807051]--[@bibr17-0269216318807051]^ symptom prevalence or health-related quality of life and their measurement tools, and comparison groups (if applicable) were recorded.

For quality assessment, J.-K.P. assessed all studies for risk of bias by using the validated review tool (QualSyst, score 0--1).^[@bibr18-0269216318807051]^ The articles scoring greater or equal to 0·8 were regarded as high quality, 0·6--0·79 as medium, while less than 0·6 as poor quality. A random 10% of the assessments were independently checked for accuracy and completeness by N.H. One review author (W.G.) resolved disagreement. Articles graded as poor quality (score \< 0·6) were not considered for final data synthesis.

For symptom prevalence of patients with end-stage liver disease, data were summarized by each symptom. As for health-related quality of life, a descriptive summary was given, and the results were combined for meta-analysis if appropriate, using a random effect model due to the degree of heterogeneity (defined if the p value of chi-square test was less than 0.1 or the I^2^ statistic was more than 40%).^[@bibr19-0269216318807051]^ Forest plots were used to display the results. Stata/SE 14 (STATA, College Station, TX) was used for all statistical analyses.

Results {#section12-0269216318807051}
=======

A total of 80 studies were included in the final review ([Figure 1](#fig1-0269216318807051){ref-type="fig"}). Electronic database searching identified 39,661 references. A total of 5473 duplicate references were removed, and a further 33,865 references were excluded after title/abstract screening and further deduplication. Seven additional studies were identified from hand searching. The full-text of 330 articles were assessed, and 87 articles were kept for quality assessment. Seven papers were graded as low quality and therefore excluded. Among the remaining, 35 described symptom prevalence and 41 provided information on health-related quality of life, while four assessed both outcomes.

![PRISMA flow diagram.](10.1177_0269216318807051-fig1){#fig1-0269216318807051}

Symptom prevalence of patients with end-stage liver disease {#section13-0269216318807051}
===========================================================

A total of 39 studies assessing symptom prevalence were included (see [Supplementary Material](http://journals.sagepub.com/doi/suppl/10.1177/0269216318807051)).^[@bibr20-0269216318807051][@bibr21-0269216318807051][@bibr22-0269216318807051][@bibr23-0269216318807051][@bibr24-0269216318807051][@bibr25-0269216318807051][@bibr26-0269216318807051][@bibr27-0269216318807051][@bibr28-0269216318807051][@bibr29-0269216318807051][@bibr30-0269216318807051][@bibr31-0269216318807051][@bibr32-0269216318807051][@bibr33-0269216318807051][@bibr34-0269216318807051][@bibr35-0269216318807051][@bibr36-0269216318807051][@bibr37-0269216318807051][@bibr38-0269216318807051][@bibr39-0269216318807051][@bibr40-0269216318807051][@bibr41-0269216318807051][@bibr42-0269216318807051][@bibr43-0269216318807051][@bibr44-0269216318807051][@bibr45-0269216318807051][@bibr46-0269216318807051][@bibr47-0269216318807051][@bibr48-0269216318807051][@bibr49-0269216318807051][@bibr50-0269216318807051][@bibr51-0269216318807051][@bibr52-0269216318807051][@bibr53-0269216318807051][@bibr54-0269216318807051][@bibr55-0269216318807051][@bibr56-0269216318807051][@bibr57-0269216318807051]--[@bibr58-0269216318807051]^ The majority reported data from North America (16) and Europe (14), although Asia (8) and Africa (1) were also covered. Most were cross-sectional studies conducted while patients were outpatients or stable after hospitalization. The patients were middle aged and predominantly male. For disease severity, 26 studies (67%) reported the percentage of patients with Child--Turcotte--Pugh class A or overall Child--Turcotte--Pugh score and 17 of 33 studies (52%) which were published between 2002 and 2018 provided Model for End-Stage Liver Disease scores. The percentage of comorbidity with hepatocellular carcinoma was reported in 18 studies (46%), ranging from 0% to 46·9%.

The instruments for symptom measurement varied across studies. For physical symptoms, most studies focused on one or two symptoms, and only three studies evaluated more than three symptoms at the same time.^[@bibr24-0269216318807051],[@bibr40-0269216318807051],[@bibr46-0269216318807051]^ The only study systematically reporting the average number of symptoms in patients with end-stage liver disease was conducted by Baumann et al., using liver-specific Edmonton Symptom Assessment System to evaluate 50 liver transplantation candidates. Among them, 80% had at least one moderate to severe symptom, and the average number of moderate to severe symptoms was 4·1.^[@bibr24-0269216318807051]^

The summary of symptom prevalence of patients with end-stage liver disease is shown in [Table 2](#table2-0269216318807051){ref-type="table"}. Pain was one of the most frequently reported symptoms across the studies with a prevalence ranging between 30% and 79%.^[@bibr36-0269216318807051],[@bibr40-0269216318807051],[@bibr43-0269216318807051],[@bibr45-0269216318807051],[@bibr46-0269216318807051]^ More specifically, Rogal et al. surveyed 193 advanced liver cirrhosis patients with a mean Child--Turcotte--Pugh score of 7.6. The authors found that 56% of patients' pain occurred at least daily, and pain-related disability was noted in 75% of the whole population. The most frequent locations of their pain were the abdomen and lower back, which was similar in another study.^[@bibr36-0269216318807051]^ Unfortunately, the pain of patients with end-stage liver disease was not well relieved. In the retrospective study conducted by Madan et al., 90% of 108 patients with end-stage liver disease were prescribed medication for pain, but only 33% of them received favorable pain relief. Furthermore, 74% of patients had already been given at least three medications for pain.^[@bibr36-0269216318807051]^ Muscle cramps were also reported in several studies, occurring in 56%--68% of patients, but the given time period of the definition of prevalence varied across studies.^[@bibr21-0269216318807051][@bibr22-0269216318807051]--[@bibr23-0269216318807051],[@bibr25-0269216318807051],[@bibr26-0269216318807051]^ Other most frequently reported physical symptoms were insomnia (26%--77%),^[@bibr28-0269216318807051],[@bibr29-0269216318807051],[@bibr38-0269216318807051],[@bibr39-0269216318807051],[@bibr42-0269216318807051],[@bibr58-0269216318807051]^ erectile dysfunction (53%--93%),^[@bibr27-0269216318807051],[@bibr32-0269216318807051],[@bibr35-0269216318807051],[@bibr48-0269216318807051],[@bibr51-0269216318807051]^ breathlessness (20%--88%),^[@bibr20-0269216318807051],[@bibr34-0269216318807051],[@bibr40-0269216318807051],[@bibr46-0269216318807051]^ and daytime sleepiness (29.5%--71%).^[@bibr28-0269216318807051],[@bibr38-0269216318807051],[@bibr39-0269216318807051],[@bibr53-0269216318807051],[@bibr55-0269216318807051]^ Fatigue and pruritus, which are regarded as disease-specific symptoms, were only reported in two articles for each, with a prevalence of 52%--86% and 47%--64%, respectively.^[@bibr25-0269216318807051],[@bibr42-0269216318807051],[@bibr56-0269216318807051],[@bibr57-0269216318807051]^ Other symptoms reported in only one article were as follows: dyspepsia (85%),^[@bibr30-0269216318807051]^ lower urinary tract symptoms (in men, 38%),^[@bibr37-0269216318807051]^ nausea (58%),^[@bibr40-0269216318807051]^ and poor appetite (49%).^[@bibr40-0269216318807051]^ The prevalence of abdominal symptoms (e.g. distension, bloating) were not reported in these studies.

###### 

Symptom prevalence of patients with end-stage liver disease.

![](10.1177_0269216318807051-table2)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Symptom                Outcome measure                         Papers using outcome measure                                                                                                                                                                                                     Prevalence (%)
  ---------------------- --------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------
  Pain                   BPI                                     Madan et al.^[@bibr36-0269216318807051]^                                                                                                                                                                                         77

                         ESAS                                    Poonja et al.^[@bibr40-0269216318807051]^                                                                                                                                                                                        65

                         MPQ                                     Rogal et al.^[@bibr43-0269216318807051]^                                                                                                                                                                                         79

                         Chart review                            Rogal et al.^[@bibr45-0269216318807051]^                                                                                                                                                                                         47

                         Interview                               Roth et al.^[@bibr46-0269216318807051]^                                                                                                                                                                                          About 30--40 (from 6 month before death)

  Breathlessness         mMRC                                    Abdel-Bary et al.,^[@bibr20-0269216318807051]^ Kaltsakas et al.^[@bibr34-0269216318807051]^                                                                                                                                      80--88

                         ESAS                                    Poonja et al.^[@bibr40-0269216318807051]^                                                                                                                                                                                        48

                         Interview                               Roth et al.^[@bibr46-0269216318807051]^                                                                                                                                                                                          About 20--45 (from 6 month before death)

  Muscle cramps          ⩾1/month for 1 year                     Abrams et al.,^[@bibr21-0269216318807051]^ Baskol et al.^[@bibr23-0269216318807051]^                                                                                                                                             62--68

                         ⩾3/month                                Angeli et al.^[@bibr22-0269216318807051]^                                                                                                                                                                                        56--57

                         ⩾1 in last month                        Bianchi et al.^[@bibr25-0269216318807051]^                                                                                                                                                                                       58

                         ⩾1 in last 12 weeks                     Chatrath et al.^[@bibr26-0269216318807051]^                                                                                                                                                                                      67

  Erectile dysfunction   IIEF-5                                  Chien et al.,^[@bibr27-0269216318807051]^ Huyghe et al.,^[@bibr32-0269216318807051]^ Wang et al.^[@bibr51-0269216318807051]^                                                                                                     74--93 (moderate--severe 17--59)

                         IIEF                                    Klein et al.^[@bibr35-0269216318807051]^                                                                                                                                                                                         53 (moderate--severe)

                         Psychiatric interview                   Sorrell and Brown^[@bibr48-0269216318807051]^                                                                                                                                                                                    54

  Insomnia               STSQS                                   De Rui et al.^[@bibr28-0269216318807051]^                                                                                                                                                                                        36

                         PSQI                                    Gencdal et al.,^[@bibr29-0269216318807051]^ Montagnese et al.,^[@bibr38-0269216318807051]^ Xiao et al.^[@bibr58-0269216318807051]^                                                                                               63--77

                         BNSQ                                    Mostacci et al.^[@bibr39-0269216318807051]^                                                                                                                                                                                      26

                         MFSI-SF                                 Rodrigue et al.^[@bibr42-0269216318807051]^                                                                                                                                                                                      73

  Daytime sleepiness     ESS                                     Abdullah et al.,^[@bibr53-0269216318807051]^ Ghabril et al.,^[@bibr55-0269216318807051]^ De Rui et al.,^[@bibr28-0269216318807051]^ Montagnese et al.,^[@bibr38-0269216318807051]^ Mostacci et al.^[@bibr39-0269216318807051]^   29.5--71

  Fatigue                FSI                                     Rodrigue et al.^[@bibr42-0269216318807051]^                                                                                                                                                                                      86

                         Self-reported questions                 Lai et al.^[@bibr56-0269216318807051]^                                                                                                                                                                                           52

  Pruritus               Baseline clinical data                  Bianchi et al.^[@bibr25-0269216318807051]^                                                                                                                                                                                       47

                         Japanese guidance                       Sumi et al.^[@bibr57-0269216318807051]^                                                                                                                                                                                          64

  Anxiety                STAI                                    Annema,^[@bibr54-0269216318807051]^ Gutteling^[@bibr31-0269216318807051]^                                                                                                                                                        25--45

                         HADS                                    Kalaitzakis et al.^[@bibr33-0269216318807051]^                                                                                                                                                                                   16

                         ESAS                                    Poonja et al.^[@bibr40-0269216318807051]^                                                                                                                                                                                        36

                         Millon behavioral medicine diagnostic   Stewart et al.^[@bibr49-0269216318807051]^                                                                                                                                                                                       14

  Depression             CES-D                                   Annema et al.,^[@bibr54-0269216318807051]^ Baumann et al.^[@bibr24-0269216318807051]^                                                                                                                                            35--36

                         BDI                                     Bianchi et al.,^[@bibr25-0269216318807051]^ Gutteling et al.,^[@bibr31-0269216318807051]^ Singh et al.^[@bibr47-0269216318807051]^                                                                                               57--64 (moderate-severe 16--28)

                         HADS                                    Kalaitzakis et al.^[@bibr23-0269216318807051]^                                                                                                                                                                                   14

                         HAM-D                                   Popovic et al.^[@bibr41-0269216318807051]^                                                                                                                                                                                       55 (moderate--severe 25)

                         ESAS                                    Poonja et al.^[@bibr40-0269216318807051]^                                                                                                                                                                                        10

                         Chart review                            Rogal et al.^[@bibr44-0269216318807051]^                                                                                                                                                                                         36

                         Millon behavioral medicine diagnostic   Stewart et al.^[@bibr49-0269216318807051]^                                                                                                                                                                                       23

                         BEF + DSM III                           Trzepacz et al.^[@bibr50-0269216318807051]^                                                                                                                                                                                      4.5 (major depression)\
                                                                                                                                                                                                                                                                                                  12.6 (adjustment disorder + depressive mood)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BDI: Beck Depression Inventory; BEF: brief evaluation form; BNSQ: Basic Nordic Sleep Questionnaire; BPI: Brief Pain Inventory; CES-D: Center for Epidemiological Studies--Depression; ESAS: Edmonton Symptom Assessment System; DSM: Diagnostic and Statistical Manual of Mental Disorders; ESS: Epworth Sleepiness Scale; FSI: Fatigue Symptom Inventory; HADS: Hospital Anxiety and Depression Scale; HAM-D: Hamilton Depression Rating Scale; IIEF: International Index of Erectile Function; MFSI-SF: Multidimensional Fatigue Symptom Inventory--Short Form; mMRC scale: modified Medical Research Council scale; MPQ: McGill Pain Questionnaire; PSQI: Pittsburgh Sleep Quality Index; STAI: State-Trait Anxiety Inventory; STSQS: Sleep Timing and Sleep Quality Screening questionnaire.

Pain: 30%--79%; breathlessness: 20%--88%; muscle cramps: 56%--68%; erectile dysfunction: 53%--93% (moderate--severe 17%--59%); insomnia: 26%--77%; daytime sleepiness: 29.5%--71%; fatigue: 52%--86%; pruritus: 47%--64%; anxiety: 14%--45%; depression: 4.5%--64% (moderate--severe 16%--28%).

Prevalence of other symptoms reported by only single study: dyspepsia (85%),^[@bibr30-0269216318807051]^ lower urinary tract symptoms (moderate--severe in men, 38%),^[@bibr37-0269216318807051]^ nausea (58%),^[@bibr40-0269216318807051]^ and poor appetite (49%).^[@bibr40-0269216318807051]^

Many of the studies also assessed psychological symptoms with a bigger focus on depression, which was reported by 11 articles. The prevalence of depression in patients with end-stage liver disease varied between 4.5% and 64%.^[@bibr24-0269216318807051],[@bibr25-0269216318807051],[@bibr31-0269216318807051],[@bibr33-0269216318807051],[@bibr40-0269216318807051],[@bibr41-0269216318807051],[@bibr44-0269216318807051],[@bibr47-0269216318807051],[@bibr49-0269216318807051],[@bibr50-0269216318807051],[@bibr54-0269216318807051]^ This may in part be related to the measurement tools used as the Beck Depression Inventory (BDI) was applied in three studies, the Center for Epidemiological Studies--Depression (CES-D) was applied in two studies, while the other six studies used six different ways to identify depressive symptoms or major depression. The prevalence of anxiety was 14%--45%,^[@bibr31-0269216318807051],[@bibr33-0269216318807051],[@bibr40-0269216318807051],[@bibr49-0269216318807051],[@bibr54-0269216318807051]^ and similarly, the five studies which assessed anxiety administered four different measurement tools.

Health-related quality of life of patients with end-stage liver disease {#section14-0269216318807051}
=======================================================================

A total of 45 studies for health-related quality of life were included (see [Supplementary Material](http://journals.sagepub.com/doi/suppl/10.1177/0269216318807051)).^[@bibr26-0269216318807051],[@bibr31-0269216318807051],[@bibr38-0269216318807051],[@bibr49-0269216318807051],[@bibr59-0269216318807051][@bibr60-0269216318807051][@bibr61-0269216318807051][@bibr62-0269216318807051][@bibr63-0269216318807051][@bibr64-0269216318807051][@bibr65-0269216318807051][@bibr66-0269216318807051][@bibr67-0269216318807051][@bibr68-0269216318807051][@bibr69-0269216318807051][@bibr70-0269216318807051][@bibr71-0269216318807051][@bibr72-0269216318807051][@bibr73-0269216318807051][@bibr74-0269216318807051][@bibr75-0269216318807051][@bibr76-0269216318807051][@bibr77-0269216318807051][@bibr78-0269216318807051][@bibr79-0269216318807051][@bibr80-0269216318807051][@bibr81-0269216318807051][@bibr82-0269216318807051][@bibr83-0269216318807051][@bibr84-0269216318807051][@bibr85-0269216318807051][@bibr86-0269216318807051][@bibr87-0269216318807051][@bibr88-0269216318807051][@bibr89-0269216318807051][@bibr90-0269216318807051][@bibr91-0269216318807051][@bibr92-0269216318807051][@bibr93-0269216318807051][@bibr94-0269216318807051][@bibr95-0269216318807051][@bibr96-0269216318807051][@bibr97-0269216318807051][@bibr98-0269216318807051]--[@bibr99-0269216318807051]^ Except for two international studies, the majority of studies reported data from Europe (21) and North America (11), and there were five from China. Most of the studies were cross-sectional and outpatient-based. The patients were mostly in their 50s and predominantly male. A total of 28 studies (62%) reported the percentage of patients with Child--Turcotte--Pugh class A or overall Child--Turcotte--Pugh score; 21 of 42 (50%) studies published between 2002 and 2018 provided Model for End-Stage Liver Disease scores. The prevalence of hepatocellular carcinoma was provided in 18 studies, ranging from 0% to 41·1%. In general, the reporting quality of articles for health-related quality of life was better than those for symptoms.

The results of the included studies for health-related quality of life of patients with end-stage liver disease are shown in the [Supplementary Material](http://journals.sagepub.com/doi/suppl/10.1177/0269216318807051). The comparisons in these articles could be categorized into four themes: disease severity, clinical status (inclusive of decompensation, lab finding, or symptoms), etiology, and other factors (e.g. demographic characteristics, social economic status). Generic health-related quality of life tools were more frequently administered than disease-specific health-related quality of life tools. The Medical Outcome Study Questionnaire 36-Item Short Form Survey (SF-36)^[@bibr100-0269216318807051],[@bibr101-0269216318807051]^ was applied in 36 studies (80%). As for disease-specific health-related quality of life tools, the Chronic Liver Disease Questionnaire (CLDQ)^[@bibr102-0269216318807051]^ was applied in 14 studies, followed by the Liver Disease Quality Of Life 1.0^[@bibr103-0269216318807051]^ (twice) and the Hepatitis Quality Of Life Questionnaire^[@bibr104-0269216318807051]^ (once).

The health-related quality of life of patients with end-stage liver disease was significantly worse, compared to normal controls or patients with chronic hepatitis. We conducted a meta-analysis of the effect of Child--Turcotte--Pugh class (Child B or C vs Child A)^[@bibr61-0269216318807051],[@bibr70-0269216318807051],[@bibr84-0269216318807051],[@bibr93-0269216318807051]^ or decompensation (decompensated vs compensated liver cirrhosis)^[@bibr38-0269216318807051],[@bibr63-0269216318807051],[@bibr67-0269216318807051],[@bibr73-0269216318807051],[@bibr79-0269216318807051],[@bibr87-0269216318807051],[@bibr92-0269216318807051]^ on the Physical Component Summary score ([Figure 2a](#fig2-0269216318807051){ref-type="fig"}) and the Mental Component Summary score ([Figure 2b](#fig2-0269216318807051){ref-type="fig"}) of the 36-Item Short Form Survey as well as CLDQ (see [Supplementary Material](http://journals.sagepub.com/doi/suppl/10.1177/0269216318807051)).^[@bibr38-0269216318807051],[@bibr62-0269216318807051],[@bibr64-0269216318807051],[@bibr74-0269216318807051],[@bibr79-0269216318807051],[@bibr93-0269216318807051],[@bibr95-0269216318807051]^ Due to heterogeneity (chi-square p \< 0.1, I^2^ statistic \> 40%), a random-effect model was applied. We found that disease progression led to significant worsening of both components of the 36-Item Short Form Survey; however, this was to a larger degree for Physical Component Summary score than for Mental Component Summary score. The decrease from average Physical Component Summary score was 6.4 (95% confidence interval (CI): 4.0--8.8; p \< 0.001) and that of average Mental Component Summary score was 4.5 (95% CI: 2.4--6.6; p \< 0.001). As to CLDQ (global score, ranging from 1 to 7), disease progression significantly worsened health-related quality of life, and the difference between each group was 0·66 (95% CI: 0.34--0.98; p \< 0.001).

![Meta-analysis of the effect of Child--Turcotte--Pugh class (Child B or C vs Child A) or decompensation (decompensated vs compensated liver cirrhosis) on the Physical Component Summary score (Figure 2a) and the Mental Component Summary score (Figure 2b) of the 36-Item Short Form Survey.](10.1177_0269216318807051-fig2){#fig2-0269216318807051}

Discussion {#section15-0269216318807051}
==========

Main findings of the study {#section16-0269216318807051}
--------------------------

This review described symptom prevalence and health-related quality of life of patients with end-stage liver disease. Pain, breathlessness, muscle cramps, sleep disturbances, and psychological symptoms are common and need to be managed carefully. Erectile dysfunction is prevalent in men with end-stage liver disease, who should be provided an opportunity for treatment. The health-related quality of life of patients with end-stage liver disease is significantly impaired when compared to healthy controls, patients with chronic liver disease or those with compensated liver cirrhosis.

This review highlighted the high degree of variability in symptom prevalence reported by different studies. This is probably owing to the within-patient variability and the differences between measurement tools. We have compared our results with that of a systematic review of symptom prevalence in advanced cancer, chronic obstructive pulmonary disease, congestive heart failure, end-stage renal disease, dementia, motor neuron disease and multiple sclerosis.^[@bibr105-0269216318807051]^ ([Table 3](#table3-0269216318807051){ref-type="table"}) The symptom prevalence of patients with end-stage liver disease resembles that of patients with these other advanced and chronic conditions. The wide range of symptoms experienced by these patients reminds healthcare professionals the importance of comprehensive and consecutive assessments for them.

###### 

Comparison of common symptom prevalence (range min to max) in end-stage liver disease and other advanced conditions.^[a](#table-fn6-0269216318807051){ref-type="table-fn"}^

![](10.1177_0269216318807051-table3)

  Symptom              ESLD      Cancer^[a](#table-fn6-0269216318807051){ref-type="table-fn"}^   COPD^[a](#table-fn6-0269216318807051){ref-type="table-fn"}^   CHF^[a](#table-fn6-0269216318807051){ref-type="table-fn"}^   ESRD^[a](#table-fn6-0269216318807051){ref-type="table-fn"}^   Dementia^[a](#table-fn6-0269216318807051){ref-type="table-fn"}^   MND^[a](#table-fn6-0269216318807051){ref-type="table-fn"}^   MS^[a](#table-fn6-0269216318807051){ref-type="table-fn"}^
  -------------------- --------- --------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------- ----------------------------------------------------------------- ------------------------------------------------------------ -----------------------------------------------------------
  Pain                 30--79    30--97                                                          21--77                                                        14--78                                                       11--83                                                        14--63                                                            52--76                                                       68
  Breathlessness       20--88    16--77                                                          56--98                                                        18--88                                                       11--82                                                        12--52                                                            81--88                                                       26
  Insomnia             26--77    3--67                                                           15--77                                                        36--48                                                       1--83                                                         14                                                                24--33                                                       
  Fatigue              52--86    23--100                                                         32--96                                                        42--82                                                       13--100                                                       22                                                                                                                             80
  Anorexia             49        76--95                                                          64--67                                                                                                                     38--64                                                                                                                                                                                       
  Nausea or vomiting   58        2--78                                                           4                                                             2--48                                                        8--52                                                         8                                                                                                                              26
  Depression           4·5--64   4--80                                                           17--77                                                        6--59                                                        2--61                                                         46                                                                23                                                           15
  Anxiety              14--45    3--74                                                           23--53                                                        2--49                                                        7--52                                                         8--72                                                             19                                                           24

ESLD: end-stage liver disease; COPD: chronic obstructive pulmonary disease; CHF: congestive heart failure; ESRD: end-stage renal disease; MND: motor neuron disease; MS: multiple sclerosis.

Adapted from Moens et al.^[@bibr105-0269216318807051]^

Data on prevalence of symptoms.

Given that end-stage liver disease affects younger age groups compared to other end-stage organ failure or terminal illness, their needs for symptom treatment and support can be different. Sexual dysfunction is a good example of this. In men with end-stage liver disease, they may have hypogonadism resulting in impotence, infertility, loss of sexual drive, or testicular atrophy. In our review, the prevalence of erectile dysfunction is 53%--93% (moderate--severe: 17%--59%).^[@bibr27-0269216318807051],[@bibr32-0269216318807051],[@bibr35-0269216318807051],[@bibr48-0269216318807051],[@bibr51-0269216318807051]^ For women with end-stage liver disease, chronic anovulation is common, which may manifest as irregular menstrual bleeding or amenorrhea,^[@bibr106-0269216318807051]^ and the prevalence of sexual dysfunction is 77.8%.^[@bibr35-0269216318807051]^ For both men and women, Sorrell and Brown.^[@bibr48-0269216318807051]^ identified that frequency of and interest in sex decreased markedly (65.3% and 40.5% each). Hence, patients with end-stage liver disease should be provided an opportunity for assessment and treatment of sexual dysfunction.

Strengths and weakness of the study {#section17-0269216318807051}
-----------------------------------

One strength of this review is that we carefully considered our eligibility criteria to identify patients with end-stage liver disease and we provide clear descriptions of important clinical characteristics of the study population (e.g. etiology, percentage of Child A according to Child--Turcotte--Pugh classification, Model for End-Stage Liver Disease score, and the percentage of hepatocellular carcinoma). In addition, this review summarized the best available evidence by searching eight electronic databases. Moreover, we were also able to perform a meta-analysis to compare the health-related quality of life between compensated and decompensated liver cirrhosis, which is of value.

Our review has several limitations. First, this is a systematic review of observational studies. We were not able to control for all potential confounders, and not all the included studies had comparison groups. However, we conducted a quality assessment and presented good-quality studies clearly to allow readers to draw their own conclusions. Second, most studies were conducted while patients were outpatients or stable after hospitalization; hence, some acute symptoms related to decompensation were not captured. Third, due to limited articles for symptom prevalence and heterogeneity of the populations, meta-analysis could not be performed in many aspects. Finally, although there was no limitation of language in the process of study identification and selection, the majority of the included studies were from Europe and North America, where the cause of end-stage liver disease, the patterns of comorbidity (e.g. hepatocellular carcinoma), and the factors associated with health-related quality of life might be different from Asian or African countries.

What this study adds {#section18-0269216318807051}
--------------------

Currently, the priority of the medical care for patients with end-stage liver disease is usually curative treatment (e.g. liver transplantation) rather than best supportive care because these patients are younger and not seen to be at the end of life by themselves or by their physicians, regardless of the risk of shortage of organs, delisting from transplantation waiting list due to contraindication, or facing life-threatening conditions.^[@bibr107-0269216318807051],[@bibr108-0269216318807051]^ The lack of holistic approach, the high prevalence of depression and anxiety, and the dearth of social support all together bring about the complexity and difficulty of caring for patients with end-stage liver disease.^[@bibr7-0269216318807051],[@bibr107-0269216318807051][@bibr108-0269216318807051][@bibr109-0269216318807051][@bibr110-0269216318807051]--[@bibr111-0269216318807051]^ Given the wide range of symptoms experienced by these patients and the significant impairment in health-related quality of life revealed by our systematic review, collaboration between primary care physicians, specialist hepatologists, liver transplantation providers, and specialist palliative care is needed.^[@bibr107-0269216318807051][@bibr108-0269216318807051]--[@bibr109-0269216318807051]^ Early detection, consecutive monitoring, and timely management of symptoms may result in better health-related quality of life in these patients. Further studies focusing on comprehensive symptom evaluation, factors related to the variation of symptomatology, and developing consensus in symptom measurement or management would be helpful.

As for the symptomatology of patients with end-stage liver disease, several disease-specific symptoms were less reported, such as abdominal symptoms, fatigue, or pruritus. Abdominal symptoms, including abdominal distension, bloating, pain, or any kind of abdominal discomfort, may worsen alongside the development of refractory ascites and induce patient distress.^[@bibr112-0269216318807051]^ On the contrary, fatigue and pruritus are common in patients with primary biliary cirrhosis or primary sclerosing cholangitis,^[@bibr113-0269216318807051],[@bibr114-0269216318807051]^ yet we found no report for either of these symptoms after decompensation. A practical way to enrich our understanding of these symptoms is to provide the raw data when measuring disease-specific health-related quality of life in future research. For instance, these symptoms are embedded in CLDQ,^[@bibr102-0269216318807051]^ Liver Disease Quality Of Life 1.0,^[@bibr103-0269216318807051]^ as well as PBC-40^[@bibr115-0269216318807051]^ for patients with primary biliary cirrhosis. Symptom prevalence can be identified from these tools. Furthermore, some other symptoms were not identified in this review and are worth exploring, including symptoms related to gastrointestinal disorder or bleeding (hematemesis, melena, hematochezia), jaundice, easy bruisability, lower extremity edema, and weight loss.

Finally, for better clarity and reporting quality of future research in patients with end-stage liver disease, we suggest that Child--Turcotte--Pugh classification (or score), Model for End-Stage Liver Disease score, and the information of comorbidity (especially hepatocellular carcinoma) should be reported. As for hepatocellular carcinoma, it is better presented considering the Milan criteria, which has been widely applied as a basis for selecting patients with hepatocellular carcinoma for liver transplantation.^[@bibr116-0269216318807051]^

Conclusion {#section19-0269216318807051}
==========

End-stage liver disease, a common cause of morbidity and mortality, disproportionally affects younger age groups and causes premature death. The symptom prevalence of patients with end-stage liver disease resembles that of patients with other advanced conditions. Given the diversity of symptoms and significantly impaired health-related quality of life, multidisciplinary approach and timely intervention are crucial. Palliative care should be integrated in the care of patients with end-stage liver disease.
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